PharVision Advisers’s Centene CNC Stock Holding History

PharVision Advisers’s Portfolio CNC Stock Details CNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,774	Closed	-$402K	–	215
2025 Q4	$402K	Buy	9,774 +3,746	+62%	+$140K	0.2%	122
2025 Q3	$215K	Buy	+6,028	New	+$182K	0.12%	454

Other funds holding CNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's CNC Position: Q1 2026 in Review

PharVision Advisers sold out of Centene (CNC) in Q1 2026, closing a stake of 9,774 shares — an estimated $402K sold.

PharVision Advisers first reported a position in CNC in Q3 2025 and held it in 2 quarters. The position peaked at $402K in Q4 2025. 863 funds tracked by Wall St. Rank hold CNC as of Q1 2026.

PharVision Advisers reported no remaining Centene position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 9,774 Centene shares in Q1 2026, an estimated $402K.
PharVision Advisers first reported a position in Centene in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Centene position peaked at $402K in Q4 2025.
863 funds tracked by Wall St. Rank held Centene as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.